TherapeuticsMD Inc (TXMD)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$2.21-1.34%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · TXMD
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. The information provided in
Results of Operations and Financial Condition. The information provided in
Changes in Registrant’s Certifying Accountant. On January 15, 2026, the Audit Committee of the Board of Directors of TherapeuticsMD, Inc., a Nevada corporation (the “Company”), approved the appointment of Carr, Riggs & Ingram, L.L.C. (“CRI”) as the Company’s independent registered public accounting firm, effective immediately. In connection therewith, Berkowitz Pollack Brant Advisors + CPAs (“BPB”), the Company’s prior independent registered public accounting firm, ceased serving as the Compa…
Results of Operations and Financial Condition. The information provided in
Results of Operations and Financial Condition. The information provided in
Results of Operations and Financial Condition. The information provided in
Other Events. On April 8, 2025, TherapeuticsMD, Inc., a Nevada corporation (the “Company”), filed a lawsuit against Mayne Pharma LLC (“Mayne Pharma”) in the United States District Court for the District of Delaware (the “Mayne Lawsuit”) seeking damages for breach of contract, breach of the implied covenant of good faith and fair dealing, fraudulent inducement, and unjust enrichment related to Mayne Pharma’s actions in relation to the License Agreement, dated December 4, 2022, as amended, betw…
Results of Operations and Financial Condition. The information provided in
Results of Operations and Financial Condition. The information provided in
Results of Operations and Financial Condition. The information provided in
Results of Operations and Financial Condition. The information provided in
Results of Operations and Financial Condition. The information provided in
Results of Operations and Financial Condition. The information provided in
Entry into a Material Definitive Agreement. On August 15, 2023 (the “Effective Date”), TherapeuticsMD, Inc., a Nevada corporation (the “Company”), entered into a Master Services Agreement (the “Master Services Agreement”) with JZ Advisory Group (“JZ”), pursuant to which, among other things, JZ will serve as an independent consultant for the purpose of providing the Company with certain support services, including the services of Joseph Ziegler as the Company’s Principal Financial Officer. The…
Principal Financial and Accounting Officer — Michael C. Donegan: Mr. Michael C. Donegan resigned from his position as Principal Financial and Accounting Officer.
Results of Operations and Financial Condition. The information provided in
Changes in Registrant’s Certifying Accountant. On July 7, 2023, the Audit Committee of the Board of Directors of TherapeuticsMD, Inc., a Nevada corporation (the “Company”) dismissed Grant Thornton LLP (“GT”) as the Company’s independent registered public accounting firm and engaged Berkowitz Pollack Brant (“BPB”) as the Company’s independent registered public accounting firm for the 2023 fiscal year. The decision to change the Company’s independent registered public accounting firm was the re…
Unregistered Sales of Equity Securities. Subscription Agreement with Rubric Capital Management LP As previously disclosed by TherapeuticsMD, Inc., a Nevada corporation (the “Company”), on a Current Report on Form 8-K filed on May 5, 2023, on May 1, 2023 the Company entered into a Subscription Agreement (the “Subscription Agreement”) with Rubric Capital Management LP (the “Investor”), pursuant to which the Company agreed to sell to the Investor, or one or more of its affiliates, up to an aggre…
Results of Operations and Financial Condition. The information provided in
Entry into a Material Definitive Agreement. Subscription Agreement with Rubric Capital Management LP On May 1, 2023, TherapeuticsMD, Inc., a Nevada corporation (the “Company”), entered into a Subscription Agreement (the “Subscription Agreement”) with Rubric Capital Management LP (the “Investor”), pursuant to which the Company agreed to sell to the Investor, or one or more of its affiliates, up to an aggregate of 5,000,000 shares of the Company’s common stock, par value $0.001 per share (the “…
Results of Operations and Financial Condition. The information provided in
Chief Executive Officer — Marlan Walker: Amendment to Employment Agreement with Mr. Marlan Walker, the Company’s Chief Executive Officer.
Interim Chief Financial Officer, Chief Accounting Officer and Vice President Finance — Michael Donegan: Mr. Donegan's employment agreement was terminated without 'Good Cause'.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. On January 6, 2023, TherapeuticsMD, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that it was not in compliance with the rules for continued listing as set forth in Nasdaq Listing Rule 5620(a) (the “Annual Meeting Rule”) due to the Company’s failure to hold an annual meeting of stockholder…
Interim Co-Chief Executive Officers and Principal Executive Officers — Dr. Brian Bernick and Mr. Mark Glickman: The company terminated Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers and Principal Executive Officers without Good Cause.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.